Sherene Loi
Sherene Loi
Peter MacCallum Cancer Centre, Melbourne, Australia
Verified email at petermac.org - Homepage
TitleCited byYear
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ...
Journal of the National Cancer Institute 98 (4), 262-272, 2006
17642006
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ...
Journal of the National Cancer Institute 98 (17), 1183-1192, 2006
12772006
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ...
Clinical cancer research 13 (11), 3207-3214, 2007
9412007
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition …
S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ...
J Clin Oncol 31 (7), 860-867, 2013
8982013
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2014
8972014
Palbociclib in hormone-receptor–positive advanced breast cancer
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
8772015
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ...
Journal of clinical oncology 25 (10), 1239, 2007
8012007
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
6892016
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
6842014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin Oncol 33 (9), 983-991, 2015
5342015
Clinical application of the 70-gene profile: the MINDACT trial
F Cardoso, L Van't Veer, E Rutgers, S Loi, S Mook, MJ Piccart-Gebhart
Journal of clinical oncology 26 (5), 729-735, 2008
5122008
CD4+ follicular helper T cell infiltration predicts breast cancer survival
C Gu-Trantien, S Loi, S Garaud, C Equeter, M Libin, A De Wind, M Ravoet, ...
The Journal of clinical investigation 123 (7), 2873-2892, 2013
4222013
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ...
New England Journal of Medicine 379 (22), 2108-2121, 2018
4082018
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
3752014
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
S Loi, B Haibe-Kains, C Desmedt, P Wirapati, F Lallemand, AM Tutt, ...
BMC genomics 9 (1), 239, 2008
3512008
Dissecting the heterogeneity of triple-negative breast cancer
O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, ...
Journal of clinical oncology 30 (15), 1879-1887, 2012
3402012
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer
S Loi, B Haibe-Kains, S Majjaj, F Lallemand, V Durbecq, D Larsimont, ...
Proceedings of the National Academy of Sciences 107 (22), 10208-10213, 2010
3362010
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
J Stagg, S Loi, U Divisekera, SF Ngiow, H Duret, H Yagita, MW Teng, ...
Proceedings of the National Academy of Sciences 108 (17), 7142-7147, 2011
3352011
Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.
C Fribbens, B O'Leary, L Kilburn, S Hrebien, I Garcia-Murillas, M Beaney, ...
3222016
Obesity and outcomes in premenopausal and postmenopausal breast cancer
S Loi, RL Milne, ML Friedlander, MRE McCredie, GG Giles, JL Hopper, ...
Cancer Epidemiology and Prevention Biomarkers 14 (7), 1686-1691, 2005
2962005
The system can't perform the operation now. Try again later.
Articles 1–20